Gonzalez Calzada Nuria, Prats Soro Enric, Mateu Gomez Lluis, Giro Bulta Esther, Cordoba Izquierdo Ana, Povedano Panades Monica, Dorca Sargatal Jordi, Farrero Muñoz Eva
a Pulmonary Department, Hospital Universitari de Bellvitge, Barcelona, Spain .
b IDIBELL Instituto de Investigación Biomédica de Bellvitge, Barcelona, Spain .
Amyotroph Lateral Scler Frontotemporal Degener. 2016 Jul-Aug;17(5-6):337-42. doi: 10.3109/21678421.2016.1165256. Epub 2016 Apr 4.
Non invasive ventilation (NIV) improves quality of life and extends survival in amyotrophic lateral sclerosis (ALS) patients. However, few data exist about the factors related to survival. We intended to assess the predictive factors that influence survival in patients after NIV initiation.
Patients who started NIV from 2000 to 2014 and were tolerant (compliance ≥ 4 hours) were included; demographic, disease related and respiratory variables at NIV initiation were analysed. Statistical analysis was performed using the Kaplan-Meier test and Cox proportional hazard models.
213 patients were included with median survival from NIV initiation of 13.5 months. In univariate analysis, the identified risk factors for mortality were severity of bulbar involvement (HR 2), Forced Vital Capacity (FVC) % (HR 0.99) and ALSFRS-R (HR 0.97). Multivariate analysis showed that bulbar involvement (HR 1.92) and ALSFRS-R (HR 0.97) were independent predictive factors of survival in patients on NIV.
In our study, the two prognostic factors in ALS patients following NIV were the severity of bulbar involvement and ALSFRS-R at the time on NIV initiation. A better assessment of bulbar involvement, including evaluation of the upper airway, and a careful titration on NIV are necessary to optimize treatment efficacy.
无创通气(NIV)可改善肌萎缩侧索硬化症(ALS)患者的生活质量并延长其生存期。然而,关于与生存相关的因素的数据却很少。我们旨在评估影响开始NIV治疗后患者生存的预测因素。
纳入2000年至2014年开始接受NIV治疗且耐受(依从性≥4小时)的患者;分析开始NIV治疗时的人口统计学、疾病相关和呼吸变量。使用Kaplan-Meier检验和Cox比例风险模型进行统计分析。
纳入213例患者,从开始NIV治疗起的中位生存期为13.5个月。单因素分析中,确定的死亡危险因素为延髓受累严重程度(HR 2)、用力肺活量(FVC)%(HR 0.99)和ALS功能评定量表修订版(ALSFRS-R)(HR 0.97)。多因素分析显示,延髓受累(HR 1.92)和ALSFRS-R(HR 0.97)是接受NIV治疗患者生存的独立预测因素。
在我们的研究中,ALS患者接受NIV治疗后的两个预后因素是开始NIV治疗时的延髓受累严重程度和ALSFRS-R。为优化治疗效果,有必要更好地评估延髓受累情况,包括对上气道的评估,并对NIV进行仔细滴定。